Virtus ETF Advisers LLC Cardiff Oncology, Inc. Transaction History

Virtus ETF Advisers LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$5.18 - $7.24 $133,488 - $186,574	-25,770 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$5.01 - $7.58 $6,733 - $10,187	-1,344 Reduced 4.96%	25,770 $172,000
Q2 2021 Aug 10, 2021	BUY	$6.65 - $10.04 $81,987 - $123,783	12,329 Added 83.39%	27,114 $180,000
Q1 2021 May 17, 2021	BUY	$9.1 - $19.57 $2,293 - $4,931	252 Added 1.73%	14,785 $137,000
Q4 2020 Feb 12, 2021	BUY	$12.02 - $24.71 $174,686 - $359,110	14,533 New	14,533 $261,000

124

21.8M

1.11M

150K

Ticker CRDF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,334,900
Market Cap $93.2M
Description
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

Stay updated on Virtus ETF Advisers LLC with notifications on news.